GLPBio

GLP-1(7-37)

Catalog No.: GC30058Purity:>99.50%
COASDSData Sheet
GLP-1(7-37) ist ein intestinales insulinotropes Hormon, das die durch Glukose induzierte Insulinsekretion verstÄrkt.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.

GLP-1(7-37)
Cas No.: 106612-94-6
1mgIn Stock
$188.00
1
5mgIn Stock
$321.00
1
10mgIn Stock
$490.00
1
25mgIn Stock
$804.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

GLP-1(7-37) is a truncated glucagon-like peptide with an EC50 value of 0.9 ± 0.1nM for GLP-1 receptors[1]. GLP-1(7-37) can bind to a specific GLP-1 receptor (GLP-1R) on pancreatic beta cells and enhance glucose-stimulated insulin secretion [2]. GLP-1(7-37) has been widely used as a model compound to develop a range of derivatives and GLP-1R agonists[3].

In vitro, GLP-1(7-37) treatment at 10nM for 30min significantly promoted cAMP generation as well as insulin secretion in Beta-TC-1 cells[4]. Pretreatment with 100nM GLP-1(7-37) for 3h enhanced the mitochondrial response to 25mM glucose stimulation in uninjured MitpHGV-MIN6 cells[5]. Treatment with 100nM GLP-1(7-37) for 10 seconds increased intracellular free calcium ions ([Ca2+]i) in COS-7 cells expressing the GLP-l receptor[6].

In vivo, GLP-1(7-37) treatment (5pmol/min/kg) via intravenous infusion (2h) into Zucker diabetic fatty (ZDF) rats transiently increased plasma insulin concentrations and normalized blood glucose concentrations[7]. Intravenous infusion of GLP-1(7-37) for 60 minutes (5pmol/min/kg) produced a transient increase in plasma insulin concentrations and a sustained slight decrease in blood glucose in fasted rats[8].

References:
[1] de Menthière C S, Chavanieu A, Grassy G, et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production[J]. European journal of medicinal chemistry, 2004, 39(6): 473-480.
[2] Vahl T P, Paty B W, Fuller B D, et al. Effects of GLP-1-(7–36) NH2, GLP-1-(7–37), and GLP-1-(9–36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans[J]. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(4): 1772-1779.
[3] Manandhar B, Ahn J M. Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications[J]. Journal of medicinal chemistry, 2015, 58(3): 1020-1037.
[4] Fehmann H C, Habener J F. Functional receptors for the insulinotropic hormone glucagon‐like peptide‐I (7–37) on a somatostatin secreting cell line[J]. FEBS letters, 1991, 279(2): 335-340.
[5] Ogata M, Iwasaki N, Ide R, et al. GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells[J]. Biochemical and Biophysical Research Communications, 2014, 447(1): 133-138.
[6] Wheeler M B, Lu M, Dillon J S, et al. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C[J]. Endocrinology, 1993, 133(1): 57-62.
[7] Hargrove D M, Nardone N A, Persson L M, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short-or long-term administration[J]. Metabolism, 1995, 44(9): 1231-1237.
[8] Hargrove D M, Nardone N A, Persson L M, et al. Comparison of the glucose dependency of glucagon-like peptide-1 (7–37) and glyburide in vitro and in vivo[J]. Metabolism, 1996, 45(3): 404-409.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

Beta-TC-1 cell

Preparation Method

Beta-TC-1 cells were grown in RPMI medium supplemented with 10% fetal bovine serum,5% horse serum, 100U/ml penicillin, and 100µg/ml streptomycin in a 95% O2, and 5% CO2 humidified atmosphere. Two days before the experiment, approximately 5×l05 cells were transferred to each well of 24-well plates. At the beginning of the cells were washed twice with KRB buffer and incubated in the medium (1ml) for 60min (37°C). Then, the buffer was changed to a buffer (300µl) containing the GLP-1(7-37) at 10nM for 30min. The entire supernatant was lyophilized and reconstituted in assay buffer for cAMP determination.

Reaction Conditions

10nM; 30min

Applications

GLP-l(7-37) treatment promoted cAMP formation in Beta-TC-1 cells.
Animal experiment [2]:

Animal models

Zucker diabetic fatty (ZDF) rat

Preparation Method

ZDF rats were housed in an environmentally controlled room (21°C with a 12-hour light/dark cycle) with food (standard rodent chow) and water available ad libitum. Fed ZDF rats were intravenously infused for 2 hours with GLP-1(7-37) at 5pmol/min/kg. Blood samples were taken from the carotid artery catheter every 15 minutes for plasma glucose and at 0, 15, 30, 60, and 120 minutes for determinations of insulin.

Dosage form

5pmol/min/kg for 2h; i.v.

Applications

GLP-l(7-37) treatment increased plasma insulin concentration and normalized the plasma glucose concentration in rats.

References:
[1] Fehmann H C, Habener J F. Functional receptors for the insulinotropic hormone glucagon?like peptide?I (7–37) on a somatostatin secreting cell line[J]. FEBS letters, 1991, 279(2): 335-340.
[2] Hargrove D M, Nardone N A, Persson L M, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short-or long-term administration[J]. Metabolism, 1995, 44(9): 1231-1237.

Produktdokumente (Product Documents)

Purity:>99.50%Appearance:A solid
COASDSData Sheet

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
106612-94-6
SMILES
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly
Summenformel
C151H228N40O47
Molekulargewicht
3355.67
Löslichkeit
Water : 30 mg/mL (8.94 mM)
Lagerung
Store at -20°C,protect from light
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for GLP-1(7-37)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%